AP2015008618A0 - Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders - Google Patents
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degradersInfo
- Publication number
- AP2015008618A0 AP2015008618A0 AP2015008618A AP2015008618A AP2015008618A0 AP 2015008618 A0 AP2015008618 A0 AP 2015008618A0 AP 2015008618 A AP2015008618 A AP 2015008618A AP 2015008618 A AP2015008618 A AP 2015008618A AP 2015008618 A0 AP2015008618 A0 AP 2015008618A0
- Authority
- AP
- ARIPO
- Prior art keywords
- compositions
- estrogen receptor
- selective estrogen
- benzothiophene derivatives
- receptor degraders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361766439P | 2013-02-19 | 2013-02-19 | |
PCT/US2014/015938 WO2014130310A1 (en) | 2013-02-19 | 2014-02-12 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2015008618A0 true AP2015008618A0 (en) | 2015-07-31 |
Family
ID=50239942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2015008618A AP2015008618A0 (en) | 2013-02-19 | 2014-02-12 | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
Country Status (46)
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014219283C1 (en) | 2013-02-19 | 2016-10-27 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
US10308871B2 (en) * | 2015-02-19 | 2019-06-04 | Jnc Corporation | Liquid crystal compound having benzothiophene, liquid crystal composition and liquid crystal display device |
TWI708770B (zh) * | 2015-06-08 | 2020-11-01 | 日商捷恩智股份有限公司 | 具有苯并噻吩的液晶性化合物、液晶組成物及液晶顯示元件 |
CN108495628B (zh) | 2015-12-09 | 2022-01-11 | 伊利诺伊大学评议会 | 苯并噻吩基选择性雌激素受体下调剂 |
CN109311870B (zh) | 2016-04-01 | 2021-09-21 | 里科瑞尔姆Ip控股有限责任公司 | 雌激素受体调节剂 |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
AR110728A1 (es) | 2017-01-06 | 2019-04-24 | G1 Therapeutics Inc | Terapia combinada para el tratamiento del cáncer |
US10208011B2 (en) | 2017-02-10 | 2019-02-19 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
US11179365B2 (en) | 2017-11-16 | 2021-11-23 | Novartis Ag | Pharmaceutical combination comprising LSZ102 and ribociclib |
CN111655288A (zh) | 2017-11-16 | 2020-09-11 | 诺华股份有限公司 | 组合疗法 |
JP2021504384A (ja) * | 2017-12-01 | 2021-02-15 | ノバルティス アーゲー | Lsz102及びアルペリシブを含む医薬品の組合せ |
IL276152B2 (en) * | 2018-01-22 | 2023-12-01 | Radius Pharmaceuticals Inc | Estrogen receptor modulating compounds |
JP7348665B2 (ja) * | 2018-02-06 | 2023-09-21 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ | 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
CA3109385A1 (en) * | 2018-08-16 | 2020-02-20 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators to treat medical disorders |
CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
WO2020165834A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN113490528A (zh) | 2019-02-15 | 2021-10-08 | 诺华股份有限公司 | 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
CA3138058A1 (en) | 2019-05-20 | 2020-11-26 | Matthew T. Burger | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
CA3148221A1 (en) | 2019-08-06 | 2021-02-11 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
AU2020406350A1 (en) | 2019-12-20 | 2022-08-11 | Novartis Ag | Uses of anti-TGF-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
CN111057065B (zh) * | 2019-12-24 | 2021-04-23 | 沈阳药科大学 | 噻吩并嘧啶类化合物的制备方法和用途 |
CN111646972B (zh) * | 2020-06-12 | 2021-06-29 | 上海皓元医药股份有限公司 | 一种选择性雌激素受体降解剂及其中间体的制备方法 |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
TW202216676A (zh) * | 2020-07-06 | 2022-05-01 | 美商塔朵根公司 | 用於心理疾病或心理強化的有益苯并噻吩組合物 |
JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
MX2023006010A (es) | 2020-11-24 | 2023-06-08 | Novartis Ag | Anticuerpos anti-cd48, conjugados de anticuerpo-farmaco, y usos de los mismos. |
IL303079A (en) | 2020-11-24 | 2023-07-01 | Novartis Ag | Antibody-drug conjugates inhibiting MCL-1 and methods of using them |
WO2022140744A1 (en) | 2020-12-23 | 2022-06-30 | Recurium Ip Holdings, Llc | Estrogen receptor modulators |
KR20230170644A (ko) | 2021-02-02 | 2023-12-19 | 르 라보레또레 쎄르비에르 | 선택적 bcl-xl protac 화합물 및 사용 방법 |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
CN116265458A (zh) * | 2021-12-17 | 2023-06-20 | 中国科学院上海药物研究所 | 苯并噻吩类衍生物、及其制备方法和用途 |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
CN115710248A (zh) * | 2022-11-18 | 2023-02-24 | 南京中医药大学 | 新型选择性雌激素受体下调剂化合物、制备方法及用途 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | 1,2‐ジアミノシクロヘキサン異性体のシス白金(2)錯体 |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
ZA822247B (en) * | 1981-04-03 | 1983-11-30 | Lilly Co Eli | Benzothiophene compounds and process for preparing them |
US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
US5589482A (en) | 1994-12-14 | 1996-12-31 | Pfizer Inc. | Benzo-thiophene estrogen agonists to treat prostatic hyperplasia |
US5510357A (en) | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
US5998441A (en) | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Benzothiophene compounds, intermediates, compositions, and methods |
PT729956E (pt) | 1995-02-28 | 2002-03-28 | Lilly Co Eli | Compostos intermediarios formulacoes e metodos de benzotiofeno |
US6417199B1 (en) | 1995-03-10 | 2002-07-09 | Eli Lilly And Company | 3-benzyl-benzothiophenes |
AU6335496A (en) | 1995-06-26 | 1997-01-30 | Eli Lilly And Company | Benzothiophene compounds |
US5731342A (en) | 1996-02-22 | 1998-03-24 | Eli Lilly And Company | Benzothiophenes, formulations containing same, and methods |
US5827876A (en) * | 1996-04-09 | 1998-10-27 | American Home Products Corporation | Inhibition of bone loss by 3-(4-acrylamidobenzoyl) benzo b!-thiophenes |
US5886025A (en) | 1997-03-06 | 1999-03-23 | Baylor University | Anti-mitotic agents which inhibit tubulin polymerization |
ZA982819B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogn receptor modulators. |
ZA982877B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
ZA982818B (en) | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Prevention of breast cancer using selective estrogen receptor modulators. |
AU3791799A (en) | 1998-05-12 | 1999-11-29 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
US6166069A (en) | 1998-05-12 | 2000-12-26 | American Home Products Corporation | Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
WO2001066098A2 (en) | 2000-03-09 | 2001-09-13 | Aventis Pharma Deutschland Gmbh | Therapeutic uses of ppar mediators |
US7091240B2 (en) | 2000-03-10 | 2006-08-15 | Oxigene, Inc. | Tubulin binding ligands and corresponding prodrug constructs |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7425565B2 (en) | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
MXPA04007402A (es) | 2002-02-01 | 2005-06-17 | Ariad Gene Therapeutics Inc | Compuestos que contienen fosforo y usos de los mismos. |
NZ534583A (en) | 2002-03-05 | 2006-11-30 | Axys Pharm Inc | Leucinamide derivatives suitable as cathepsin cysteine protease inhibitors |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
DE60327931D1 (de) | 2002-07-22 | 2009-07-23 | Lilly Co Eli | Selektive östrogenrezeptor modulatoren, die eine phenylsulfonyl-gruppe enthalten |
DE602004016331D1 (de) | 2003-06-10 | 2008-10-16 | Lilly Co Eli | Pentafluoroalkylsulfin-naphthaline und und darauf bezogene modulatoren des östrogenrezeptors |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
US20070066595A1 (en) | 2004-01-22 | 2007-03-22 | Dodge Jeffrey A | Selective estrogen receptor modulators |
US20070111988A1 (en) | 2004-01-22 | 2007-05-17 | Eli Lilly And Company | Selective estrogen receptor modulators |
US20080227814A1 (en) | 2004-01-29 | 2008-09-18 | Jeffrey Alan Dodge | Selective Estrogen Receptor Modulators |
ATE532768T1 (de) | 2004-09-02 | 2011-11-15 | Genentech Inc | Pyridylinhibitoren der hedgehog-signalvermittlung |
CA2599987A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JP2010521475A (ja) | 2007-03-16 | 2010-06-24 | イーライ リリー アンド カンパニー | アルゾキシフェンを調製するためのプロセスおよび中間体 |
CL2008002687A1 (es) | 2007-09-12 | 2009-01-16 | Genentech Inc | Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico. |
US20090069380A1 (en) | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched aroxifene |
WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
CN102477033A (zh) * | 2010-11-23 | 2012-05-30 | 苏州波锐生物医药科技有限公司 | 苯并噻酚类化合物及其在制备预防和/或治疗乳腺癌骨质疏松症药物中的用途 |
CA2819299A1 (en) | 2010-12-24 | 2012-06-28 | Merck Sharp & Dohme B.V. | N-substituted azetidine derivatives |
AU2014219283C1 (en) | 2013-02-19 | 2016-10-27 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
-
2014
- 2014-02-12 AU AU2014219283A patent/AU2014219283C1/en not_active Ceased
- 2014-02-12 KR KR1020157025506A patent/KR102279999B1/ko active IP Right Grant
- 2014-02-12 WO PCT/US2014/015938 patent/WO2014130310A1/en active Application Filing
- 2014-02-12 HU HUE14708992A patent/HUE039052T2/hu unknown
- 2014-02-12 ME MEP-2018-102A patent/ME03061B/me unknown
- 2014-02-12 NZ NZ710385A patent/NZ710385A/en not_active IP Right Cessation
- 2014-02-12 PT PT147089924T patent/PT2958907T/pt unknown
- 2014-02-12 US US14/768,341 patent/US9321746B2/en active Active
- 2014-02-12 DK DK14708992.4T patent/DK2958907T3/en active
- 2014-02-12 TR TR2018/06882T patent/TR201806882T4/tr unknown
- 2014-02-12 EP EP14708992.4A patent/EP2958907B1/en active Active
- 2014-02-12 GE GEAP201413917A patent/GEP201706638B/en unknown
- 2014-02-12 US US14/178,652 patent/US8877801B2/en active Active
- 2014-02-12 EA EA201591537A patent/EA028032B1/ru not_active IP Right Cessation
- 2014-02-12 BR BR112015018882-6A patent/BR112015018882B1/pt not_active IP Right Cessation
- 2014-02-12 SG SG11201505697VA patent/SG11201505697VA/en unknown
- 2014-02-12 AP AP2015008618A patent/AP2015008618A0/xx unknown
- 2014-02-12 JP JP2015558090A patent/JP6364028B2/ja active Active
- 2014-02-12 LT LTEP14708992.4T patent/LT2958907T/lt unknown
- 2014-02-12 MX MX2015010752A patent/MX359471B/es active IP Right Grant
- 2014-02-12 MA MA38325A patent/MA38325B1/fr unknown
- 2014-02-12 CN CN201480009342.8A patent/CN105008343B/zh active Active
- 2014-02-12 RS RS20180412A patent/RS57106B1/sr unknown
- 2014-02-12 MY MYPI2015702659A patent/MY174888A/en unknown
- 2014-02-12 PE PE2015001768A patent/PE20151428A1/es unknown
- 2014-02-12 ES ES14708992.4T patent/ES2671516T3/es active Active
- 2014-02-12 CU CUP2015000090A patent/CU24337B1/es unknown
- 2014-02-12 PL PL14708992T patent/PL2958907T3/pl unknown
- 2014-02-12 CA CA2899030A patent/CA2899030C/en active Active
- 2014-02-12 SI SI201430679T patent/SI2958907T1/en unknown
- 2014-02-12 EP EP18156411.3A patent/EP3360870A1/en not_active Withdrawn
- 2014-02-18 UY UY0001035334A patent/UY35334A/es not_active Application Discontinuation
- 2014-02-18 JO JOP/2014/0038A patent/JO3494B1/ar active
- 2014-02-18 TW TW103105338A patent/TWI612040B/zh not_active IP Right Cessation
- 2014-02-19 AR ARP140100517A patent/AR094704A1/es unknown
- 2014-10-06 NO NO14795784A patent/NO3077717T3/no unknown
-
2015
- 2015-07-21 ZA ZA2015/05305A patent/ZA201505305B/en unknown
- 2015-07-23 IL IL240131A patent/IL240131B/en active IP Right Grant
- 2015-07-27 CL CL2015002098A patent/CL2015002098A1/es unknown
- 2015-07-31 TN TN2015000323A patent/TN2015000323A1/en unknown
- 2015-08-13 NI NI201500106A patent/NI201500106A/es unknown
- 2015-08-19 DO DO2015000202A patent/DOP2015000202A/es unknown
- 2015-08-19 GT GT201500233A patent/GT201500233A/es unknown
- 2015-08-19 PH PH12015501832A patent/PH12015501832B1/en unknown
- 2015-08-19 CR CR20150424A patent/CR20150424A/es unknown
-
2016
- 2016-01-04 HK HK16100013.5A patent/HK1211941A1/zh not_active IP Right Cessation
- 2016-03-10 US US15/066,425 patent/US9561211B2/en active Active
-
2017
- 2017-01-05 US US15/399,562 patent/US9931317B2/en active Active
-
2018
- 2018-02-17 US US15/898,561 patent/US10058534B2/en active Active
- 2018-04-27 CY CY20181100447T patent/CY1120155T1/el unknown
- 2018-05-23 HR HRP20180816TT patent/HRP20180816T1/hr unknown
- 2018-08-17 HK HK18110605.6A patent/HK1251227A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1251227A1 (zh) | 作為選擇性雌激素受體降解劑的苯並噻吩衍生物及其組合物 | |
HRP20180817T1 (hr) | Sastavi i postupci za modulaciju farnesoid-x-receptora | |
HK1214532A1 (zh) | 雌激素受體調節劑及其用途 | |
ZA201600067B (en) | Intumescent composition | |
EP2970569A4 (en) | PERSISTENT CARBENES AND ASSOCIATED COMPOSITIONS | |
IL246299A0 (en) | History of Sorbibin and preparations containing them | |
EP2968165A4 (en) | COMPOSITIONS AND RELATED METHODS FOR RADIOISOTOPE BINDING MICROPARTICLES | |
HK1220200A1 (zh) | 乙炔基衍生物 | |
EP2968698A4 (en) | COMPOUNDS AND COMPOSITIONS FOR RELEASE OF MEDICAMENT | |
IL240019A0 (en) | Estrogen receptor inhibitors | |
EP2958568A4 (en) | PHOSPHAPLATINES AS NEUROPROTECTIVE AGENTS | |
PL2757142T3 (pl) | Kompozycja zmniejszająca opór | |
HK1214131A1 (zh) | 包含氫化可的松的組合物 | |
AP2013006754A0 (en) | Pylon |